Key terms
About TECH
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TECH news
May 02
10:10am ET
Bio-Techne price target raised to $83 from $80 at Scotiabank
May 02
9:41am ET
Analysts’ Top Healthcare Picks: Bio-Techne (TECH), Gilead Sciences (GILD)
May 02
8:31am ET
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Atricure (ATRC) and Bio-Techne (TECH)
May 02
7:20am ET
Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN) and Bio-Techne (TECH)
May 02
6:19am ET
Bio-Techne price target raised to $81 from $73 at Baird
May 02
4:05am ET
KeyBanc Remains a Buy on Bio-Techne (TECH)
May 02
4:03am ET
Analysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Amneal Pharmaceuticals (AMRX)
May 01
6:36am ET
Bio-Techne reports Q3 adjusted EPS 48c, consensus 45c
Apr 30
9:48pm ET
RBC Capital Sticks to Its Hold Rating for Bio-Techne (TECH)
Apr 30
4:43pm ET
Bio-Techne Board Expansion and Strategic Director Appointments
Apr 29
11:29am ET
Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
Apr 29
7:05am ET
Bio-Techne announces new distribution agreement with Thermo Fisher
Apr 26
7:09am ET
Bio-Techne and Novomol-Dx announces development of Bio-Marker Pathfinder
Apr 23
7:12am ET
Bio-Techne takes legal action in the Unified Patent Court in Europe
Apr 23
7:04am ET
Bio-Techne files patent infringement suit against Molecular Instruments
Apr 18
5:36am ET
Bio-Techne price target lowered to $82 from $85 at Deutsche Bank
Apr 08
9:46pm ET
RBC Capital Reaffirms Their Hold Rating on Bio-Techne (TECH)
Apr 04
5:45am ET
Buy Rating Affirmed for Bio-Techne Amid Market Recovery and Strategic Positioning
Mar 28
9:04am ET
Bio-Techne and Nikon partner for spatial biology services
Mar 22
7:02am ET
Bio-Techne receives European IVDR certification for diagnostic test
Feb 08
9:44am ET
Alibaba downgraded, Disney upgraded: Wall Street’s top analyst calls
Feb 08
7:01am ET
Bio-Techne initiated with an Outperform at Scotiabank on market-leading growth
Feb 07
4:19pm ET
Bio-Techne initiated with an Outperform at Scotiabank
Feb 05
4:05am ET
Bio-Techne: Solid Consumables Business and Strategic Investments Anchor Buy Rating Amid Sector Headwinds
No recent press releases are available for TECH
TECH Financials
Key terms
Ad Feedback
TECH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TECH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
